The Spectranetics Corp

The Spectranetics — Spectranetics — Technical Presentation (January 2017)

16 slides from The Spectranetics's technical presentation, Jan 24, 2017

  1. Slide 1: ILLUMENATE Global Study Stellarex DCB

    Prof. Thomas Zeller Department of Angiology University Heart Center Freiburg-Bad Krozingen Bad Krozingen, Germany On behalf of Dr. Andrew Holden, Prof. Yann Gouëffic and the ILLUMENATE Global Investigators ILLUMENATE Global Study Stellarex DCB

  2. Slide 2: Disclosures

    Disclosures Speaker Name: Prof. Thomas Zeller I have the following potential conflicts of interest to report: Consulting: Medtronic, Bard, Biotronik, Trireme, Spectranetics, Boston Scientific Employment in industry Stockholder of a healthcare company Owner of a healthcare company Other(s) I do not h

  3. Slide 3: ILLUMENATE Global Study Overview

    ILLUMENATE Global Study Overview  Prospective, multi-center, single-arm, study  Patients will be followed for up to 5 years Same rigorous data collection process as randomized trials, independent adjudication by: • Angiographic Core Laboratory1 • Duplex Ultrasound Core Laboratory2 • Clinical Event

  4. Slide 4: ILLUMENATE Global Study Overview: Objective and Endpoints

    ILLUMENATE Global Study Overview  Study Objective: Assess safety and performance of the Stellarex DCB in the SFA and/or popliteal arteries  Primary Safety Endpoint: Freedom from device- and procedure-related death through 30 days and freedom from target limb major amputation and CD-TLR through 12

  5. Slide 5: Study Device: Stellarex DCB

    5 Study Device: Stellarex DCB Stellarex (2 µgr/mm2) DCB Comp. A (3.5 µgr/mm2) DCB Comp. B (2.0 µgr/mm2) Arterial Pharmaco-Kinetics [1] PTX particulate loss after transit [2] • Low dose (2 μg/mm2) paclitaxel • Hybrid-crystalline formulation Spectranetics Proprietary open-folded coating technology 1.

  6. Slide 6: Key Patient Eligibility Criteria

    Key Patient Eligibility Criteria Inclusion Criteria • Rutherford class 2, 3 or 4 • SFA and/or popliteal (down to trifurcation) • Has at least one patent run-off below-the-knee • 1 or 2 target lesion(s) with cumulative length ≤ 20 cm • Target vessel reference diameter 4-6 mm Exclusion Criteria • Acut

  7. Slide 7: Baseline Patient Characteristics

    Baseline Patient Characteristics N (patients) 371 Age 68.2 ± 9.3 (371) Male 73.0% (271/371) Diabetes 33.7% (125/371) Body Mass Index 27.0 ± 4.2 (368) Hypertension 79.5% (295/371) Hyperlipidemia 74.7% (277/371) Previous or Current smoker 81.9% (304/371) Previous coronary revasc. 33.4% (124/371) Renal

  8. Slide 8: Baseline Angiographic Characteristics

    Baseline Angiographic Characteristics Per Core Lab assessment N (lesions) 417 De novo1 94.0% (392/417) Lesion Length (cm) 7.5 ± 5.3 (413) Total occlusions 31.3% (129/412) Calcification None/Mild 43.0% (173/402) Moderate 16.2% (65/402) Severe calcification 40.8% (164/402) Minimum lumen diameter (mm)

  9. Slide 9: Procedural Characteristics

    Procedural Characteristics Pre-dilatation1 98.1% (409/417) Post-dilatation1 28.3% (118/417) Provisional stent1 17.3% (72/417) Stent Due to Dissection1 8.65% (36/417) Post-DCB Dissections Grade D Flow-limiting (Grade E or F) 19.7% (81/416) 0.2% (1/416) Post-DCB MLD (mm) 3.43 ± 0.80 (407) Post-procedu

  10. Slide 10: Key Safety Endpoints

    Key Safety Endpoints  Freedom from Primary Safety Event: 94.8%*  All-cause mortality through 12 Months*: 0.6% (2/355)  Cause of both deaths was cancer  CD-TLR rate through 12 months*: 6.2% (22/354) Primary Safety Events Device- or procedure-related death 0 Major target limb amputation 1** Clinic

  11. Slide 11: Freedom From CD-TLR by Clinical Events Committee Adjudication

    Freedom From CD-TLR* by Clinical Events Committee Adjudication * Defined as revascularization associated with PSVR ≥ 2.5 or >50% stenosis via angiogram and worsening of RCC by more than 1 or ABI decrease of >0.15 from the maximum early post-procedure level, that is clearly referable to the target le

  12. Slide 12: Primary Patency by Duplex Core Lab Evaluation

    Primary Patency by Duplex Core Lab Evaluation Primary Patency defined as freedom from Duplex derived restenosis (PSVR ≤ 2.5) and clinically-driven TLR 81.4% @ day 365 Day 0 30 180 360 365 395 At Risk 417 411 398 260 217 70 Event 0 5 14 51 65 84 Survival (%) 100 98.8 96.6 86.6 81.4 69.1 360

  13. Slide 13: 12-Month Patency Rates Data in Context with Core Lab Adjudicated Trials

    1. Lyden S. Oral presentation, TCT 2016, Washington DC. Nov 2, 2016. 2. Brodmann M. Oral presentation. AMP Symposium, Chicago, IL, Aug 10, 2016 3. Laird JR et al. J Am Coll Cardiol 2015;66:2329-38, P.Krishnan Oral Presentation. VIVA 2016 4. Rosenfield K, Jaff MR, White CJ, et al. The New England Jou

  14. Slide 14: 12-Month CD-TLR and Ca++ Data in Context with Core Lab Adjudicated Trials

    1. Lyden S. Oral presentation, TCT 2016, Washington DC. Nov 2, 2016. 2. Brodmann M. Oral presentation. AMP Symposium, Chicago, IL, Aug 10, 2016 3. French National Commission of Medical Device Evaluation on IN.PACT SFA (May, 3rd 2016) - http://www.has-sante.fr/portail/jcms/c_2635037/fr/in-pact-admira

  15. Slide 15: Key Secondary Outcomes: Rutherford Classification and WIQ Score

    0% 0.3% 34.8% 56.3% 6.5% 2.1% 61.1% 19.2% 12.1% 6.8% 0% 0.9% RCC 0 RCC 1 RCC 2 RCC 3 RCC 4 RCC 5 Baseline 12 Months Key Secondary Outcomes Rutherford Classification* *analysis includes patients with RCC data at baseline and 12 months (n=339) P<0.001  90.3% of subjects had an improvement in Rutherfo

  16. Slide 16: ILLUMENATE Global Conclusions

    ILLUMENATE Global Conclusions • ILLUMENATE Global demonstrated a 12-month Primary patency of 81.4% and CD-TLR rate of 6.2% • Data support and reinforce previous findings from ILLUMENATE Pivotal trial in a similarly high (>40%) severe calcium patient cohort • Builds on the robust ILLUMENATE program w

Spectranetics — Technical Presentation (January 2017) on 6ix